This is the authors' abstract. We don't add key points for this paper.
The pharmacokinetics of cefotaxime was investigated in 6 healthy subjects and in 22 uraemic patients with various degrees of renal insufficiency. After i.v. bolus injection of a single 15 mg/kg dose, pharmacokinetic data were calculated using a three-compartment open body model. In healthy subjects , after i.v. injection, the mean terminal serum half-life T ½ β was 1.44 ± 0.45 h and apparent volume of distribution V darea was 34.23 ± 9.19 1/1.73 m 2 . After a similar i.m. dose, the mean peak serum level was 25.32 ± 3.94 mg/l, the elimination T½ was 1.07 ± 0.14 h and bioavailability was 91.5±14.8 %. Fifty to sixty per cent of the injected dose was recovered unchanged in 24 h urines. Renal and serum clearances were 170 and 280 ml/min/1.73 m 2 , respectively. In uraemic patients , after a single 15 mg kg i.v. dose, T ½ β increased in relation to degree of renal impairment up to 10.81 ± 3.23 h in patients with creatinine clearance (C cr ) lower than 8 ml/min/1.73 m 2 . In haemodialysis patients, T ½ β was out of dialysis 8.96 ± 6.47 h and on a 4 to 6 h-dialysis session 1.98 ± 0.72 h. 62.3 ± 17.4 % of the drug was extracted by dialysis. The apparent volume of distribution was not significantly modified by renal insufficiency. Relationships between pharmacokinetic data ( T ½ β,) and biological parameters of renal function (serum creatinine, C cr ) provide a basis for dosage adjustment in renal failure.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Fillastre et al. (1980) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: